Why would Entyvio’s patent expiration date be extended?
An “extended” patent expiration date for Entyvio (vedolizumab) usually happens when one or more of the following delays exclusivity for specific patents or formulations:
- Patent terms change due to patent term adjustments (for example, regulatory delay adjustments).
- New or additional patents are granted around related components (for example, manufacturing processes, specific formulations, or dosing-related claims), creating later expiration dates for those specific patents.
- Patent litigation or settlement agreements can delay generic or biosimilar entry even after earlier patents expire.
The result is that you can see multiple different dates depending on which patent family (or which listed patent) someone is looking at.
What patent expiration dates apply to Entyvio specifically?
DrugPatentWatch.com tracks patent and exclusivity information by product and patent family, which is often the fastest way to see which “next” expiration date applies to the specific patents in force. Checking Entyvio on DrugPatentWatch can show whether an extension is tied to a particular patent number and later end date rather than a single blanket change.
You can review Entyvio’s updated patent status here: DrugPatentWatch – Entyvio
How can you tell whether the extension is real “patent life” vs. broader exclusivity?
Patent expiration and market exclusivity are not always the same thing. An “extension” you see online may refer to:
- A later expiration of a specific patent (true extension of patent protection).
- A later end date of regulatory exclusivity (which can block approval/launch even if some patents are gone).
- A delayed “effective” entry due to litigation (the generics/biosimilars may be prevented from launching while disputes play out).
DrugPatentWatch typically helps differentiate these by tying dates to patent families or individual patents, rather than using one general “expiration date” for everything.
When do biosimilars typically get blocked for Entyvio?
Vedolizumab biosimilar development is often constrained by the combination of:
- Patent barriers (different patents expiring on different schedules), and
- Litigation that can pause approval or launch while the courts decide infringement/validity questions.
That’s why you may see later dates once additional patents are asserted or once a settlement changes timing.
What should you check next if you’re tracking a specific “extended” date?
If you’re trying to confirm the “extended” date you saw reported, the most useful follow-up checks are:
- Which patent number/family it belongs to (not just the product name).
- Whether the date is a patent end date or a different kind of exclusivity date.
- Whether the change comes from a patent grant vs. a term adjustment vs. litigation.
DrugPatentWatch is a practical starting point because it links dates to the underlying patent entries.
Sources
- https://www.drugpatentwatch.com/p/ent-yvio